海曲泊帕对比血小板生成素促进异基因造血干细胞移植后血小板植入的疗效与安全性:一项前瞻性、多中心、随机对照临床试验
该前瞻性多中心随机对照试验将212例异基因造血干细胞移植患者于输注后第3天随机分为低剂量海曲泊帕组(2.5 mg/天)、高剂量海曲泊帕组(5 mg/天)和对照组(血小板生成素300 U/kg/天)。结果显示海曲泊帕组血小板植入中位时间13天快于对照组15天(p=0.0022),中性粒细胞植入亦加速(13 vs 15天,p=0.0001),原发性血小板恢复失败发生率较低(5.04% vs 13.7%,p=0.027),且低剂量与高剂量疗效相当。
要点
- 海曲泊帕组血小板植入中位13天,快于对照组15天(p=0.0022),两剂量间无差异(p=0.0593)。
- 海曲泊帕组中性粒细胞植入中位13天,快于对照组15天(p=0.0001)。
- 海曲泊帕组原发性血小板恢复失败发生率5.04%,低于对照组13.7%(p=0.027)。
核心结论
- 海曲泊帕可安全加速异基因造血干细胞移植后血小板和中性粒细胞植入,降低原发性血小板恢复失败风险,减少输血依赖。
- 低剂量海曲泊帕疗效与高剂量相当,为改善移植结局提供了一种经济有效的策略。
研究设计与样本
- 前瞻性、多中心、随机对照临床试验,于输注后第3天将接受异基因造血干细胞移植的患者随机分为低剂量海曲泊帕组(2.5 mg/天)、高剂量海曲泊帕组(5 mg/天)或对照组(血小板生成素300 U/kg/天)。
- 共分析212例患者,终点包括血小板/中性粒细胞植入时间、原发性血小板恢复失败发生率、输血需求和安全性。
- 试验注册号:ChiCTR2200057764。
主要发现
- 海曲泊帕组血小板植入中位时间13天,对照组15天(p=0.0022),两剂量组间无差异(p=0.0593)。
- 海曲泊帕组中性粒细胞植入中位时间13天,对照组15天(p=0.0001)。
- 海曲泊帕组原发性血小板恢复失败发生率为5.04%,对照组为13.7%(p=0.027)。
- 海曲泊帕组血小板输注需求更少(p=0.002),消化道出血减少,费用更低。
- 继发性血小板恢复失败组间无差异。
关键数值与推荐
- 低剂量海曲泊帕2.5 mg/天与高剂量5 mg/天疗效相当。
- 对照组血小板生成素剂量为300 U/kg/天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is pivotal for hematological malignancies but faces challenges in delayed platelet engraftment, poor graft function (PGF), and bleeding risks. Hetrombopag, a thrombopoietin receptor agonist, was evaluated to enhance platelet recovery posttransplant. Patients undergoing allo-HSCT were randomized on Day 3 Post-Infusion into low-dose (2.5 mg/day), high-dose (5 mg/day) hetrombopag groups, or a control group receiving thrombopoietin (300 U/kg/day). Endpoints included platelet/neutrophil engraftment time, PGF incidence, transfusion needs, and safety. Among 212 analyzed patients, platelet engraftment was faster in hetrombopag groups (median 13 days) versus controls (15 days; p = 0.0022), with no dose-dependent difference (p = 0.0593). Neutrophil engraftment was also accelerated (13 vs. 15 days; p = 0.0001). PGF incidence was lower in hetrombopag groups (5.04%) versus controls (13.7%; p = 0.027). The experimental group required fewer platelet transfusions (p = 0.002), had reduced gastrointestinal bleeding, and lower costs. Secondary platelet recovery failure showed no intergroup differences. Hetrombopag safely accelerates platelet and neutrophil engraftment, reduces PGF risk, and decreases transfusion dependency post-allo-HSCT. Low-dose hetrombopag demonstrated efficacy equivalent to high-dose, offering a cost-effective strategy to improve transplant outcomes. Trial Registration: ChiCTR2200057764.
引用
- Feng Y, Wang L, Ren M, et al. Efficacy and Safety of Hetrombopag Versus Thrombopoietin in Promoting Platelet Engraftment After Allogeneic Hematopoietic Stem Cell Transplantation: A Prospective, Multicenter, Randomized Controlled Clinical Trial. Am J Hematol. 2025. PMID: 40536084. doi:10.1002/ajh.27746
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。